Bristol-Myers Squibb Company ($BMY) Stock Forecast: Down 5.4% Today

What is Bristol-Myers Squibb Company?

Bristol Myers Squibb (BMY) is a pharmaceutical company recognized for its innovative drug portfolio and research in various therapeutic areas. The stock market saw significant downward movement today.

Why is Bristol-Myers Squibb Company going down?

BMY stock is down 5.4% on Jul 31, 2025 19:46

• BMY posted robust Q2 earnings and sales figures, surpassing expectations – typically prompting a bullish market response. However, missing EPS estimates and reducing the 2025 EPS guidance likely led to the bearish outlook.
• Uncertainty surrounding the company's future earnings potential may have triggered the negative market reaction, despite a positive sales forecast.
• Investors could be exercising caution due to conflicting analyst recommendations, with some advising to adopt a wait-and-see strategy before the Q2 results.
• The bearish movement in BMY's stock today might have been influenced by the overall market sentiment towards pharmaceutical stocks and broader economic conditions.

BMY Price Chart

BMY Technical Analysis

BMY News

Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View

BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.

https://www.zacks.com/stock/news/2644530/bristol-myers-beats-on-q2-earnings-and-sales-raises-25-sales-view

Why Is Bristol Myers Stock Falling Thursday? - Bristol-Myers Squibb ( NYSE:BMY )

Q2 revenue rose to $12.27 billion, beating estimates; EPS of $1.46 missed the $1.58 consensus. 2025 EPS guidance cut to $6.35-$6.65; sales outlook raised to $46.5 billion-$47.5 billion. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

https://www.benzinga.com/markets/earnings/25/07/46760485/bristol-myers-cuts-earnings-outlook-as-legacy-drugs-face-generic-erosion

Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday - Apple ( NASDAQ:AAPL ) , Amazon.com ( NASDAQ:AMZN )

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Apple Inc. AAPL to report quarterly earnings at $1.42 per share on revenue of $89.04 billion after the closing bell, according to data from ...

https://www.benzinga.com/news/25/07/46746815/microsoft-apple-and-3-stocks-to-watch-heading-into-thursday-2

Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.

https://www.zacks.com/stock/news/2628596/should-you-buy-hold-or-sell-bmy-stock-ahead-of-q2-earnings

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.2% Today

XRP ($XRP) Crypto Forecast: Down 5.1% Today

Cardano ($ADA) Crypto Forecast: Down 5.1% Today

Chainlink ($LINK) Crypto Forecast: Down 5.4% Today

Lithia Motors Inc. ($LAD) Stock Forecast: Up 5.1% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.0% Today

Transdigm Group Incorporated Inc. ($TDG) Stock Forecast: Down 12.7% Today

Eaton Corporation PLC ($ETN) Stock Forecast: Down 6.7% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 7.2% Today

Pfizer Inc. ($PFE) Stock Forecast: Up 5.0% Today

Bristol-Myers Squibb Company Price History

04.03.2025 - BMY Stock was down 5.0%

• The bearish movement in BMY stock could be attributed to the overall market uncertainty and volatility caused by global trade tensions and tariff threats.
• Despite a positive opinion for label expansion of Opdivo, BMY's flagship drug, broader economic concerns and fears of a recession may have impacted market sentiment.
• Market fluctuations have been likened to Disney's Tower of Terror ride, illustrating the unpredictable nature of current market conditions.
• Investors may be approaching pharmaceutical stocks like BMY cautiously due to market turbulence, resulting in the bearish movement despite positive company developments.

07.02.2025 - BMY Stock was up 5.6%

• BMY outperformed the market with a strong bullish movement, closing higher than the previous day.
• The positive movement could be attributed to potential positive clinical trial results or regulatory approvals for one of its key drugs.
• Investors might be optimistic about BMY's future revenue prospects, leading to increased buying activity.
• The company's strong performance despite the overall market decline showcases investor confidence in BMY's resilience and growth potential.

31.09.2024 - BMY Stock was up 6.5%

• The anticipation of Bristol Myers' upcoming Q3 earnings report and the positive outlook on its new drugs have likely contributed to the bullish movement.
• Despite the overall market gains, the slight dip in BMY's stock price from the prior day's close could be attributed to profit-taking or minor market fluctuations.
• Investors seem optimistic about the company's future prospects, especially with the recent positive regulatory updates, which may have further boosted confidence in BMY's performance.

31.09.2024 - BMY Stock was up 5.0%

• Bristol-Myers Squibb (BMY) witnessed a strong bullish movement recently, fueled by its impressive third-quarter results and heightened annual earnings guidance.
• The company's performance was buoyed by surpassing earnings and sales projections, as well as robust demand for its blood thinner medication and new drugs, resulting in revenue growth.
• Positive regulatory developments and the robust adoption of new drugs have bolstered the stock's upward trajectory, positioning it as an appealing choice for investors.
• Despite a slight decline in the stock price in the latest trading session, the overall optimistic outlook and growth potential have propelled Bristol-Myers Squibb (BMY) ahead in the market.

25.06.2025 - BMY Stock was down 2.7%

• The stock of Bristol-Myers Squibb Inc. (BMY) experienced a strong bearish movement today.
• The disappointing news of Bristol Myers' drug, Reblozyl, failing in a blood cancer-associated anemia trial likely contributed to the bearish market movement.
• Investors may have reacted negatively to the drug's failure to meet the primary endpoint of 12-week RBC transfusion independence, impacting the stock price.
• The market sentiment could have been further dampened by the uncertainty surrounding the future prospects of Reblozyl and its potential impact on the company's revenue and growth trajectory.

08.06.2025 - BMY Stock was up 2.6%

• BMY shares closed at $47.51, indicating a significant 2.64% increase from the previous trading session.
• Despite a slight drop earlier in the day, BMY managed to rally and outperform the market, showcasing resilience.
• The positive movement in BMY could be attributed to investor optimism surrounding the company's financial performance and potential growth prospects in the pharmaceutical sector.
• The overall bullish market sentiment likely provided further support to BMY's upward trajectory, as investors sought opportunities in stable and promising stocks like Bristol-Myers Squibb.

30.06.2024 - BMY Stock was down 5.5%

• Analyst Carter Gould revised BMY's rating to Underweight while upholding the price target at $41, potentially impacting the downtrend.
• The mixed analyst sentiment and recent stock movements discussed by a financial expert may have intensified the selling pressure on BMY shares.
• The prevailing bearish sentiment surrounding BMY stands in contrast to the upbeat earnings season, hinting at specific company-specific factors causing the downturn.
• The adverse forecasts from prominent Wall Street analysts and the broader market movement affecting stocks like BMY, Abbive, and Tesla likely contributed to the downward pressure on Bristol-Myers Squibb's stock.

10.03.2025 - BMY Stock was down 6.1%

• The FDA approval for the label expansion of Opdivo plus Yervoy combo for colorectal cancer reflects positively on BMY, showcasing the company's dedication to addressing unmet medical needs.
• Despite this favorable development, the stock faced a bearish trend today, possibly due to investors taking profits, considering the approval had already been factored into the stock price.
• Investor apprehensions regarding the competitive environment in oncology or overall market conditions may have led to the sell-off of BMY shares, despite the encouraging regulatory update.
• Investors are advised to evaluate the long-term implications of BMY's extended label approval and its potential impact on the company's revenue and market standing in the oncology sector.

31.06.2025 - BMY Stock was down 5.6%

• Bristol-Myers Squibb (BMY) stock had a bearish movement today, potentially attributed to investors taking a cautious stance ahead of the company's Q2 earnings release.
• The expectations for BMY's Q2 results, where growth drugs are forecasted to offset some declines, may have caused uncertainty among investors, leading to the bearish trend.
• With the earnings report eagerly awaited, investors are likely adopting a "wait and see" strategy, adding to the downward pressure on BMY stock.
• While tech giants like Apple and Amazon are in the spotlight today, the pharmaceutical sector, represented by BMY, appears to be garnering a more subdued market reaction.

31.06.2025 - BMY Stock was down 5.9%

• Bristol-Myers Squibb posted Q2 revenue of $12.27 billion, exceeding expectations. However, their EPS of $1.46 missed the consensus of $1.58, leading to disappointment among investors.
• The company's decision to reduce the 2025 EPS guidance to $6.35-$6.65 could have influenced the market sentiment, despite an increase in the sales forecast to $46.5 billion-$47.5 billion.
• Uncertainties regarding the company's future performance, including the challenges of new product launches alongside declining legacy products, may be prompting investors to adopt a more cautious stance, resulting in the stock's downward trajectory on the latest trading day.

31.06.2025 - BMY Stock was down 5.4%

• BMY posted robust Q2 earnings and sales figures, surpassing expectations – typically prompting a bullish market response. However, missing EPS estimates and reducing the 2025 EPS guidance likely led to the bearish outlook.
• Uncertainty surrounding the company's future earnings potential may have triggered the negative market reaction, despite a positive sales forecast.
• Investors could be exercising caution due to conflicting analyst recommendations, with some advising to adopt a wait-and-see strategy before the Q2 results.
• The bearish movement in BMY's stock today might have been influenced by the overall market sentiment towards pharmaceutical stocks and broader economic conditions.

14.04.2025 - BMY Stock was down 5.1%

• The stock price of Bristol-Myers Squibb declined notably following the company's agreement to pay $350 million to the State of Hawaiʻi for resolving claims tied to the prescription drug Plavix. Such substantial legal settlements have the potential to impact a company's financial standing and influence investor confidence, contributing to the bearish market activity.
• Today's 1.20% drop in BMY shares may also be a result of investors reassessing the stock's price-to-earnings ratio. Given the recent stock price decrease over the past month and a history of fluctuations, investors may be realigning their positions, further fueling the prevailing bearish sentiment.
• Despite witnessing a positive upturn of 4.70% in the past year, the recent legal settlement and broader market conditions could have overshadowed this growth, culminating in the observed bearish trajectory today.